Wellington Management Group
ABOS icon

Wellington Management Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Wellington Management Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-112,258
Closed -$455K – 1875
2024
Q1 		$455K Buy
+112,258
New +$423K ﹤0.01% 1821
2023
Q4 		– Sell
-104,359
Closed -$433K – 1815
2023
Q3 		$433K Buy
+104,359
New +$645K ﹤0.01% 1712

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Wellington Management Group's ABOS Position: Q2 2024 in Review

Wellington Management Group sold out of Acumen Pharmaceuticals (ABOS) in Q2 2024, closing a stake of 112,258 shares — an estimated $455K sold.

Wellington Management Group first reported a position in ABOS in Q3 2023 and held it in 2 quarters. The position peaked at $455K in Q1 2024. 81 funds tracked by Wall St. Rank hold ABOS as of Q2 2024.

  • Wellington Management Group reported no remaining Acumen Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Wellington Management Group sold 112,258 Acumen Pharmaceuticals shares in Q2 2024, an estimated $455K.
  • Wellington Management Group first reported a position in Acumen Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Wellington Management Group's Acumen Pharmaceuticals position peaked at $455K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2024.

Based on Wellington Management Group's 13F filing for Q2 2024, filed 14 Aug 2024.